Применение пероральных антикоагулянтов в лечении больных с острым коронарным синдромом

Research outputpeer-review

Abstract

The review discusses the results of using oral anticoagulants to improve the prognosis of patients after exacerbation of coronary artery disease. Based on a review of the available randomized clinical trials, the authors conclude that rivaroxaban at a dose of 2.5 mg twice daily has the best efficacy/safety ratio. Administration of rivaroxaban at the mentioned dose within 1 year after the development of acute coronary syndrome helps to reduce cardiovascular and total mortality and the risk of stent thrombosis.

Translated title of the contributionORAL ANTICOAGULANTS IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
Original languageRussian
Pages (from-to)28-43
JournalАтеротромбоз
Issue number1
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Применение пероральных антикоагулянтов в лечении больных с острым коронарным синдромом'. Together they form a unique fingerprint.

Cite this